Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 53

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 53
---
| • |     | Enfusion’s or Clearwater’s ability to implement its respective business strategy; |

| • |     | significant transaction costs associated with the Transactions; |

| • |     | the possibility that the Transactions may be more expensive to complete than anticipated, including as a result 
 of unexpected factors or events;                                                                                |

| • |     | potential litigation relating to the Transactions; |

| • |     | the risk that disruptions from the Transactions will harm Enfusion’s or Clearwater’s business, 
 including current plans and operations;                                                        |

| • |     | the ability of Enfusion or of Clearwater to retain and hire key personnel; |

| • |     | potential adverse reactions or changes to business relationships of Enfusion or of Clearwater resulting from the 
 announcement or completion of the proposed transaction;                                                          |

| • |     | legislative, regulatory and economic developments, including as a result of the change in U.S. presidential 
 administration, affecting Enfusion’s or Clearwater’s business;                                              |

| • |     | general economic and market developments and conditions; |

| • |     | the legal, regulatory and tax regimes under which Enfusion or Clearwater operates; |

29

| • |     | potential business uncertainty, including changes to existing business relationships, during the pendency of the 
 Transactions that could affect Enfusion’s or Clearwater’s financial performance;                                 |

| • |     | the risk that any announcements relating to the Transactions could have adverse effects on the market price of 
 Enfusion Common Stock or Clearwater Common Stock;                                                              |

| • |     | restrictions during the pendency of the Transactions that may impact Enfusion’s or Clearwater’s ability 
 to pursue certain business opportunities or strategic transactions;                                     |

| • |     | Clearwater’s ability to successfully integrate Enfusion’s operations into Clearwater’s business; |

| • |     | unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or 
 outbreak of war or hostilities;                                                                           |

| • |     | the finalization and audit of Enfusion’s 2024 fiscal year financial results which could potentially result 
 in changes or adjustments to the preliminary financial results previously presented; and                   |

| • |     | Enfusion’s or Clearwater’s response to any of the aforementioned factors. |

Clearwater and Enfusion caution that the foregoing list of factors is not exhaustive. Additional information concerning these and other risk factors is contained in Clearwater’s and Enfusion’s most recently filed